GT200300191A - Dibencenoxazepinas - Google Patents

Dibencenoxazepinas

Info

Publication number
GT200300191A
GT200300191A GT200300191A GT200300191A GT200300191A GT 200300191 A GT200300191 A GT 200300191A GT 200300191 A GT200300191 A GT 200300191A GT 200300191 A GT200300191 A GT 200300191A GT 200300191 A GT200300191 A GT 200300191A
Authority
GT
Guatemala
Prior art keywords
compounds
dibencenoxazepins
othership
vitronectine
aterosclerosis
Prior art date
Application number
GT200300191A
Other languages
English (en)
Inventor
Claudia Hirth-Dietrich
Jacques Dumas
Elisabeth Woltering
Beatrix Stelte-Ludwig
Dmitri Zubov
Michael Brands
Peter Ellinghaus
Dirk Heimbach
Johannes Koebberling
Karl-Heinz Schlemmer
Siegfried Zaiss
Franz Zumpe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300191A publication Critical patent/GT200300191A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA I EN LA QUE R1,R2,R3,R4,N,M,Y, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DEL FIBRINOGENO Y/O VITRONECTINA POR LO QUE SON DE UTILIDAD EN CASOS DE PATOLOGIAS CARDIOCIRCULATORIAS COMO ATEROESCLEROSIS, PRINCIPALMENTE, PERO TAMBIEN, DADA LAS CARACTERISTICAS DE SU MECANISMO DE ACCION ES DE UTILIDAD EN CUADROS INFLAMATORIOS, AUTOINMUNES, ENTRE OTRAS DESCRITAS EN LA SOLICITUD.
GT200300191A 2002-09-13 2003-09-09 Dibencenoxazepinas GT200300191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10242488A DE10242488A1 (de) 2002-09-13 2002-09-13 Dibenzoxazeptine

Publications (1)

Publication Number Publication Date
GT200300191A true GT200300191A (es) 2004-05-12

Family

ID=31895918

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300191A GT200300191A (es) 2002-09-13 2003-09-09 Dibencenoxazepinas

Country Status (15)

Country Link
EP (1) EP1539721A1 (es)
JP (1) JP2006503869A (es)
KR (1) KR20050057305A (es)
CN (1) CN1694876A (es)
AR (1) AR040907A1 (es)
AU (1) AU2003266336A1 (es)
BR (1) BR0314109A (es)
CA (1) CA2498658A1 (es)
DE (1) DE10242488A1 (es)
GT (1) GT200300191A (es)
MX (1) MXPA05002702A (es)
PL (1) PL375563A1 (es)
TW (1) TW200413340A (es)
UY (1) UY27973A1 (es)
WO (1) WO2004033437A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004004928A1 (de) * 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
WO2009071631A2 (en) * 2007-12-05 2009-06-11 Janssen Pharmaceutica Nv Dibenzoazepine and dibenzooxazepine trpa1 agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) * 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
JPS58225073A (ja) * 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd ジベンゾオキサゼピノン誘導体
JP2002537260A (ja) * 1999-02-17 2002-11-05 メルク エンド カムパニー インコーポレーテッド αＶインテグリン受容体拮抗薬としてのジベンゾ−アゼピン誘導体

Also Published As

Publication number Publication date
EP1539721A1 (de) 2005-06-15
JP2006503869A (ja) 2006-02-02
PL375563A1 (en) 2005-11-28
DE10242488A1 (de) 2004-03-25
WO2004033437A1 (de) 2004-04-22
MXPA05002702A (es) 2005-06-08
CN1694876A (zh) 2005-11-09
UY27973A1 (es) 2004-04-30
AU2003266336A1 (en) 2004-05-04
TW200413340A (en) 2004-08-01
CA2498658A1 (en) 2004-04-22
AR040907A1 (es) 2005-04-20
BR0314109A (pt) 2005-07-26
KR20050057305A (ko) 2005-06-16

Similar Documents

Publication Publication Date Title
GT200500101A (es) Compuestos de metil-aril o heteroaril-amida sustituida
GT200600107A (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200400013A (es) Compuestos de pirazolotriazina y usos de los mismos
GT200800103A (es) 5-aril isoxazolinas para controlar plagas de invertebrados
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200400173A (es) Compuestos de aril o heteroaril amida
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200800258A (es) Compuestos de pirrolo-pirimidina y sus usos
GT200500008A (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
GT200300226A (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos
GT200400032A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf)
GT200100160A (es) Derivados 4-fenil-piridina.
ECSP045255A (es) Cumarinas utiles como biomarcadores
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
CR9260A (es) COMPUESTOS DE BIS ARILO Y HETEROARILO SUSTITUIDOS COMO ANTAGONISTAS SELECTIVOS DE 5HT2a
GT200300031A (es) Indazoles substitutos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
GT200200269A (es) Derivados de 7-amino-benzotiazol
GT200300258A (es) Activadores de ppar
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
GT200200280A (es) Lactamas como antagonistas de taquiquininas
GT200300033A (es) Derivados de nicotinamida utiles como inhibidores de pde4
GT200600326A (es) Diazepinoquinolinas, sintesis de las mismas e intermediarios de las mismas
GT200300263A (es) Derivados de indazol como antagonistas del crf